Literature DB >> 26077940

Early rebleeding in patients with subarachnoid haemorrhage under intensive blood pressure management.

Motoki Oheda1, Joji Inamasu2, Shigeta Moriya1, Tadashi Kumai1, Yushi Kawazoe1, Shunsuke Nakae1, Yoko Kato1, Yuichi Hirose1.   

Abstract

The objective of this study was to report the frequency and clinical characteristics of early rebleeding in subarachnoid haemorrhage (SAH) patients who underwent intensive blood pressure (BP) management. Patients with aneurysmal SAH frequently present to the emergency department (ED) with elevated BP. Intensive BP management has been recommended to lower the risk of early rebleeding. However, few studies have reported the frequency of early rebleeding in SAH patients undergoing BP management. In our institution, SAH patients with systolic BP (SBP)>140 mmHg received continuous intravenous nicardipine to maintain their SBP within 120±20 mmHg after diagnosis. An attempt to implement intensive BP management was made on 309 consecutive SAH patients who presented to our ED within 48 hours of SAH onset. Overall, 24 (7.8%) of the 309 patients sustained early rebleeding. Fifteen patients sustained early rebleeding before the implementation of BP management, and the other nine sustained early rebleeding after the implementation of BP management. Therefore, the frequency of early rebleeding under BP management was 3.1% (9/294). When the 309 patients were dichotomised using ED SBP of 140 mmHg as a cut off (SBP>140 mmHg; n=239 versus SBP⩽140 mmHg; n=70), the latter counter-intuitively exhibited a significantly higher frequency of early rebleeding (5.9% versus 14.2%; p=0.04). This relatively low frequency of early rebleeding under BP management may be acceptable. However, early rebleeding is not eradicated even with strict BP control as factors other than elevated BP are involved. ED SBP within the target range (SBP⩽140 mmHg) does not negate the risk of early rebleeding. Other treatment options that reduce the risk should also be explored.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood pressure; Early rebleeding; Nicardipine; Subarachnoid haemorrhage

Mesh:

Substances:

Year:  2015        PMID: 26077940     DOI: 10.1016/j.jocn.2015.02.024

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

Review 1.  Interventions for altering blood pressure in people with acute subarachnoid haemorrhage.

Authors:  Mathias Maagaard; William K Karlsson; Christian Ovesen; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2021-11-17

Review 2.  ED BP Management for Subarachnoid Hemorrhage.

Authors:  W Denney Zimmerman; Wan-Tsu W Chang
Journal:  Curr Hypertens Rep       Date:  2022-05-24       Impact factor: 4.592

Review 3.  Subarachnoid hemorrhage in the emergency department.

Authors:  Sima Patel; Amay Parikh; Okorie Nduka Okorie
Journal:  Int J Emerg Med       Date:  2021-05-12

Review 4.  Blood Pressure in Acute Stroke and Secondary Stroke Prevention.

Authors:  Christopher R Green; J Claude Hemphill
Journal:  Curr Neurol Neurosci Rep       Date:  2022-03-25       Impact factor: 5.081

5.  Rebleeding After Aneurysmal Subarachnoid Hemorrhage in Two Centers Using Different Blood Pressure Management Strategies.

Authors:  Lionel Calviere; Celine S. Gathier; Marie Rafiq; Inez Koopman; Vanessa Rousseau; Nicolas Raposo; Jean François Albucher; Alain Viguier; Thomas Geeraerts; Christophe Cognard; Gabriel J E Rinkel; Mervyn D I Vergouwen; Jean-Marc Olivot
Journal:  Front Neurol       Date:  2022-02-21       Impact factor: 4.003

Review 6.  Aneurysmal Subarachnoid Hemorrhage: the Last Decade.

Authors:  Sean N Neifert; Emily K Chapman; Michael L Martini; William H Shuman; Alexander J Schupper; Eric K Oermann; J Mocco; R Loch Macdonald
Journal:  Transl Stroke Res       Date:  2020-10-19       Impact factor: 6.829

Review 7.  Lessons from the CONSCIOUS-1 Study.

Authors:  Alexander J Schupper; Matthew E Eagles; Sean N Neifert; J Mocco; R Loch Macdonald
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.